the variables age, sex, BMI, albumin, Kt/V and D/Pcreat at 6 months of treatment indicated that low Background. Loss of residual renal function has a profound effect on the survival of peritoneal dialysis Kt/V (P=0.004), high D/P creat (P=0.013) and age (P=0.028) were independent predictors of death. patients. Less is known of the impact of peritoneal function. The purpose of this study was to investigate Conclusion. There is good reason to believe that high peritonel solute transport is an independent marker of the influence of solute transport on clinical outcome in CAPD patients.
made of weight, body mass index (BMI ), plasma Introduction albumin, Kt/V, residual renal function (RRF ), NPCR, low-molecular-weight solute transport (D/P creat ), and Several factors are now known to be related to clinical peritoneal protein losses. All patients were censored in outcome in patients treated with continuous ambulat-1996, regardeless of treatment modality.
ory peritoneal dialysis (CAPD). Adverse factors Results. During the 6-year follow up period (median include age, comorbid disease, poor nutritional state 22 months) there were 51 deaths, and the actuarial and low plasma albumin at onset of treatment, and survival was 58% at 5 years. Urea, protein and peritonthe dialysis dose ( Kt/V ), particularly as manifested by eal kinetics varied with time on dialysis: as anticipated the loss of residual renal function [1] [2] [3] [4] [5] [6] [7] . There is also there was a reduction in Kt/V, attributable to loss of growing evidence that peritoneal function, as assessed RRF, whereas plasma albumin was stable for the first by low-molecular-weight solute transport and ultrafil-2 years of treatment, but subsequently started to tration capacity can influence outcome, both in relation decline, a trend that became significant at 42 months.
to technique failure and certain types of comorbidity Peritoneal kinetics stabilized within the first 6 months [8] [9] [10] . Defining an independent role for peritoneal of treatment and then showed a trend of increased function as a predictor, let alone determinant, of solute transfer with time on treatment, which became patient survival is complicated by two factors: firstly significant by the end of the study.
the interrelationships between these predictive markers, Comparing survivors with non-survivors Kt/V and and secondly their tendency to change with time on RRF were similar at the start of treatment, but loss of treatment. For example, both solute transport and RRF occurred significantly earlier in non-survivors peritoneal protein losses are proportional to the effectthan survivors (0.37 vs 0.68, P=0.02 at 6 months, 0.19 ive peritoneal surface area, such that D/P creat will vs 0.54, P=0.01 at 12 months). D/P creat was also co-vary with plasma albumin [2, 11] . Furthermore, the identical at commencement of treatment, but subimpact of poor peritoneal ultrafiltration (which is sequently whilst survivors had stable solute transfer, associated with high transport) will be masked by the non-survivors had consistently higher solute transfer presence of good residual renal function, which in turn beyond 6 months that reached increasing significance is lost with time on CAPD, whilst progressive changes after 18 months, (0.70 vs 0.67, P=0.05 at 18 months, in peritoneal function might be occurring [12] . A fuller 0.72 vs 0.66, P=0.03 at 24 months).
understanding of how these factors interact with each A Cox proportional hazard model constructed for other, and thus play a deterministic role in clinical outcome is clearly desirable if this treatment modality establish how urea, protein and peritoneal kinetics
The dialysate:plasma ratio of creatinine at the completion of develop over the first 4 years of CAPD in a homogenthe 4-h dwell period, (D/P creat ), was used as the estimate of eous group of patients in whom there were no systemlow-molecular-weight solute transfer. As glucose interferes atic attempts to alter or maintain Kt/V, in order to with the assay for creatinine in a linear fashion, concentraestablish if solute transport is related to clinical tions for both these solutes are measured at 4 h and the true outcome.
value for creatinine obtained by subtracting the glucose concentration multiplied by a correction factor derived locally by our laboratory (0.47). Using this method the 4-h
Subjects and methods
D/P creat is a highly reproducible measure of low-molecularweight solute transfer across a wide range of values (0.45-0.9), in the short term (3 months or less provided
Patient population and study design
there has been no clinical event such as peritonitis or surgery), with a coefficient of variation of 3-5%. Normal ranges±95% This was a single-centre, prospective, longitudinal observa-CI, 0.635±0.25 for D/P creat and 498±409 ml for net tional study. All of 210 patients commencing on the CAPD ultrafiltration. programme between 1990 and 1995 inclusive, regardless of aetiology of renal failure and comorbid diseases, were enrolled into the study. Patient data was collected at Statistical analysis 6-monthly outpatient assessments which included a biochemical profile, full 24-h dialysate collection, and peritoneal Actuarial survival following entry to the study was performed equilibration test from which the Kt/V, RRF, low-molecular-using the Kaplan-Meier method. Cox's proportional hazard weight solute transport (D/P creat ), 24-h protein losses, and regression model was used in the multivariate analyses, protein catabolic rate (PCR) were calculated. Patient demo-utilising chi-squared for significance testing, adopting a graphy including age, height, body mass index (BMI ), and manual stepwise approach for the six variables, age, Kt/V, sex were recorded on entry to the study, and patient death plasma albumin, solute transport, sex, and BMI [16 ] . was the clinical end-point.
Comparisons between Kt/V, RRF, plasma albumin, and peritoneal function in survivors versus non-survivors at
Dialysis dose (Kt/V)
different time-points were made using non-paired Student t test, whereas longitudinal changes were analysed using an The dialysis dose was assessed by calculating the weekly ANOVA. Kt/V urea from the 24-h urinary and dialysate clearance, by direct measurement of urea in urine and from each dialysate exchange. The volume of distribution for urea was estimated Results as 58% of the body dry weight . Results are expressed as the total weekly Kt/V urea (peritoneal and renal components), or The mean age of the patient population was 52.8 years,
for the residual renal function (RRF ) alone.
(median 57, range 14-80), with a mean height of 1.67 m, and male:female sex ratio of 58542.The
Protein catabolic rate (PCR)
Kaplan-Meier actuarial survival plot for the whole population is shown in Figure 1 , along with numbers This was calculated using the equation derived from detailed of patients at risk. Of 210 patients who entered, 51 nitrogen balance studies in CAPD patients: PCR (g/day)= died during the study period, and the actuarial survival (0.261·UA (mmol/day))+13+TPL (g/day), where UA is the at 5 years was 58% (see Figure 1 ). All patients were total (urine plus dialysate) urea appearance and TPL is the censored at the end of the study period regardless of total (urine plus dialysate) protein loss over 24 h. PCR was normalized for dry body-weight (NPCR) [13] .
Analytical methods
Plasma and dialysate concentrations of urea, creatinine and glucose were determined on an automated discrete random access analyser (DAX 72, Bayer Instruments, Basingstoke, UK ). Urine and dialysate total protein estimations were made using the Biuret method. Plasma albumin levels were measured using the bromocresol green method.
Peritoneal equilibration test (PET)
The peritoneal equilibration test was used to measure peritoneal kinetics, and this was performed as described previously [12, 14, 15] . Briefly, a standard 4-h dwell period was used (first exchange of the day), using a 2.27% glucose concentration 2-litre volume exchange. The patients used their usual overnight dialysis regime, and both the overnight and test was calculated as the difference between the 2 litres of the treatment modality at that point, and a total of 48 months of treatment there was a significant drop in the plasma albumin. This reduction in the plasma 102 patients were not on CAPD for various reasons, although the median time spent on CAPD was 22 albumin occurred at the same time that there was an increase in the LMW solute transfer, and was associmonths (mean 27 months). Of the 51 patients who had died, 25 died on CAPD, five following transplantation ated with a rise in the calculated protein clearances, although this did not reach statistical significance. and 21 following transfer to unit haemodialysis. There were 45 renal transplants and 28 CAPD technical
The comparison of the longitudinal changes in plasma albumin in survivors with non-survivors is failures (in addition to the deaths), 17 due to recurrent peritonitis, 11 due to ultrafiltration failure. Of these illustrated in Figure 2 . It can be seen that plasma albumin at the commencement of treatment is significpatients transferring to haemodialysis, 65% with recurrent peritonitis and 54% with ultrafiltration failure died antly lower in non-survivors, but that this difference disappears subsequently until the later stages of treatbefore the close of the study. Four patients requested transfer to haemodialysis out of choice, three of whom ment, although it does not reach statistical significance. Figure 3 shows a similar representation for the total survived. Because of the relatively high number of endpoints occurring after transfer from CAPD an analysis Kt/V and RRF with time in survivors and nonsurvivors. Whilst Kt/V was similar in at the commenceof these patients was carried out. Of these deaths, 81% occurred within 6 months of transfer, and when the statistical analyses were performed excluding those patients with longer that 6 months survival on a different treatment modality there was no difference in the overall findings (see below).
Longitudinal changes in clinical parameters
The longitudinal changes in urea kinetics ( Kt/V, RRF, and NPCR), protein kinetics (plasma albumin, total protein losses) and peritoneal kinetics (D/P creat ratios and ultrafiltration volumes) are summarized for the whole study population in Table 1 .
During the first 18 months of dialysis treatment there was a rapid and significant decline in the total Kt/V, due entirely to the loss of residual renal function. over the 48 months of observation, whereas at 42 and As can be seen from the model in Table 2 by far the most important predictor of survival in this was significantly (*P<0.05) faster in non-survivors (%) compared patient population at 6 months. This is entirely to survivors (&).
explained by the impact of residual renal function, as would be anticipated from the shapes of the curves in Figure 3 , and the model is not altered by substituting this for total Kt/V. As would be anticipated increased age is an independent predictor of death. In addition, high solute transport was associated independently with poor survival, whereas plasma albumin, body mass index, and sex were not independent predictors. When those patients who died more than 6 months after discontinuing CAPD were excluded from the data analysis, Kt/V (P=0.0045), solute transport (P= 0.032), but not age (P=0.09) remained independent predictors of survival. population of patients treated in a single centre with conventional CAPD. Evidence from a variety of longitment of treatmant, and both groups of patients lost udinal and cross-sectional studies have implicated all RRF following commencement of CAPD, this was these factors as important predictors or even determinsignificantly more rapid in the non-survivors, in whom ants of clinical outcome on CAPD [1-8], but this is the majority of loss was within the first 6 months of the first study to examine all three elements and their treatment. A similar plot for longitudinal changes in interrelationships prospectively over several years. As peritoneal solute transfer (D/P creat ) with time in sur-a result, whilst the importance of loss of residual renal vivors and non-survivors ( Figure 4) , was rather differ-function and a low plasma albumin are clearly apparent in its pattern. D/P creat was identical for both groups ent, peritoneal kinetics are also seen to be independat the commencement of treatment, and increased ently linked to survival. significantly at 6 months, by which time the solute The longitudinal changes observed in urea kinetics transfer was higher in non-survivors. Subsequently, are, as would be anticipated, dominated by the loss in whilst solute transfer remained stable in survivors over residual renal function. This is approximately exponenthe next 4 years, there was an increasing disparity due tial with time, with a half-life between 18 and 24 to elevated D/P creat in the non-survivors. months of treatment. The resultant drop in total Kt/V is accompanied by a steady decline in the NPCR, suggesting that the relationship between urea clearance
Prediction of clinical outcome
and total urea and protein nitrogen appearance is not simply a mathematical one, a problem that has beset the interpretation of cross-sectional studies [18] . Whilst A Cox's proportional hazard model was constructed for the principle variables under investigation (plasma this cannot be taken as proof that dialysis dose and protein intake are causally related, it does provide albumin, Kt/V, and peritoneal solute transport) and supportive evidence of a longitudinal relationship. The The longitudinal changes in protein kinetics demonstrated a yet different pattern with time on CAPD. actual values obtained for Kt/V and NPCR during the first 24 months of this study are similar but not The mean plasma albumin remained stable for the first 36 months of treatment, but subsequently there was a identical to the larger, multicentre CANUSA study [6 ] . These differences, however, are systematic and can significant fall seen in this patient cohort. Total protein losses, after the small initial drop due to reduced be attributed to the different methods used in their calculation. As yet there is still no reliable but simple protein losses from RRF, remained remarkably stable over the subsequent 4 years. This is despite the observaway of estimating the volume of distribution of urea in CAPD patients, a problem particularly observed in tion that peritoneal permeability to proteins appears to decrease with time on CAPD [21] . The explanation obese patients, and there is a tendency for the Watson formula to give lower estimates for V, resulting in the for this is the large influence that molecular size has on the permeability of the peritoneum to proteins. generally higher values for Kt/V than are seen here [19] . Whichever method used, the influence of residual Albumin, a relatively small protein, is in quantitative terms by far the most significant protein present in renal function on the interpatient variability of total Kt/V and subsequent survival was so strong that dialysate effluent, and its losses are therefore more sensitive to changes in size of the effective peritoneal simililar results were obtained. The relatively higher values for NPCR obtained in this study compared to surface area than to peritoneal permeability [11] . The tendency for patients in this study to have increasing CANUSA reflect the use of an equation derived by Bergstrom et al. [13] from detailed nitrogen balance D/P creat , particularly after 30 months of treatment, raises the possibility that the lower plasma albumin studies in CAPD patients, which also takes peritoneal protein losses into account. Again, whilst the methods levels are due to increased peritoneal protein clearances. Although calculated protein clearances after 3 differ [20] , the general message that both KL/V and NPCR decline on CAPD due to loss in RRF is years tended to be higher, this does not reach statistical significance, suggesting that this is not the only the same.
The longitudinal peritoneal kinetics observed in this explanation, and raising the possibility that the low plasma albumin levels reflected a degree of cohort were, as would be expected, similar to those already described for the first 166 of these patients in overhydration.
In summarizing this part of the study it is apparent detail elsewhere [12] . The early increase in D/P creat , a consistent feature on our unit, would suggest that if that during the first 36 months of CAPD there is a gradual decline in Kt/V due to the loss in RRF, whilst the PET is done too early in the course of CAPD that it may not reflect the true effective peritoneal surface protein and peritoneal kinetics remain stable; there is subsequently a drop in plasma albumin and increase area. This is supported by the fact that at 6 months there was a stronger correlation between D/P creat and in low-molecular-weight solute transfer. Throughout treatment there a consistent relationship between body surface area. Subsequently peritoneal kinetics remain stable until 36 months, after which the mean plasma albumin, dialysate protein losses and peritoneal kinetics, but none of these factors covary on cross-D/P creat starts to increase. There is also a gradual reduction in ultrafiltration, although the PET is less sectional analysis with the dialysis dose.
The second objective of this study was to establish precise in its quantification of this problem. Both these changes are seen despite a preferential loss of patients how these various factors relate to patient survival.
Whilst age is a powerful and independent predictor of with high solute transfer and poor ultrafiltration consequent to frequent peritonitis from both death and clinical outcome, this is not the case for sex or patient size, corroborating the findings of other studies. As in technical failure [12] . This would imply that a proportion of patients on CAPD aquire high solute transport the CANUSA study [6 ] , mortality is associated with the failure to maintain the total Kt/V during the first with time, that is accelerated by but not conditional on multiple peritonitis episodes.
2 years of CAPD treatment. The loss in residual renal function is considerably more rapid in non-survivors, but require either automated PD or alternative osmotic agents that can achieve sustained ultrafiltration. with the majority of this loss occurring within the first 6 months of treatment. Whilst CANUSA expressed
